Linked Life Data

16787796

Source:http://linkedlifedata.com/resource/pubmed/id/16787796

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-6-21
pubmed:abstractText
Ibutilide is a type III antiarrhythmic agent approved for the pharmacologic conversion of atrial fibrillation (AF) and atrial flutter (AFl). Previous studies conducted outside the ED setting have demonstrated conversion rates of 60% to 80%. This response has been highest in patients with recent-onset AF-AFl. These observations and the 4-hour half-life of ibutilide suggest that it may be an excellent drug with which to treat AF-AFl in the ED. The purpose of the study was to examine the efficacy and safety of ibutilide in terminating AF-AFl in patients who present to the ED with symptoms of less than 3 days' duration, neither angina nor heart failure, and no comorbid conditions that require admission.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0735-6757
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
407-12
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Ibutilide to expedite ED therapy for recent-onset atrial fibrillation flutter.
pubmed:affiliation
Internal Medicine and Cardiology Department, Livadia General Hospital, 32100 Livadia, Greece, and Internal Medicine and Cardiology Department, Yale University/Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT 06610, USA. mountas@ccf.org
pubmed:publicationType
Journal Article, Clinical Trial